{
  "legislationId": "119_HR_8269",
  "lastUpdate": "2026-04-18T11:23:46.193Z",
  "history": [
    {
      "timestamp": "2026-04-18T11:23:46.193Z",
      "source_url": "https://www.congress.gov/119/bills/hr8269/BILLS-119hr8269ih.htm",
      "model": "gemini-flash-lite-latest",
      "prompt_sent": "\nROLE: Fact Checker.\nZADANIE: Porównaj SOURCE (oryginał) i SUMMARY (streszczenie przygotowane przez inne AI).\n\nTwoim celem jest wykrycie \"ZMYŚLONYCH KONKRETÓW\" (Fabricated Entities) w SUMMARY.\n\nSOURCE:\n[Congressional Bills 119th Congress] [From the U.S. Government Publishing Office] [H.R. 8269 Introduced in House (IH)] <DOC> 119th CONGRESS 2d Session H. R. 8269 To amend the Federal Food, Drug, and Cosmetic Act to require drug labeling to include original manufacturer and supply chain information. _______________________________________________________________________ IN THE HOUSE OF REPRESENTATIVES April 14, 2026 Mr. McCormick (for himself and Ms. DeLauro) introduced the following bill; which was referred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned _______________________________________________________________________ A BILL To amend the Federal Food, Drug, and Cosmetic Act to require drug labeling to include original manufacturer and supply chain information. Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled, SECTION 1. SHORT TITLE. This Act may be cited as the ``Consumer Labeling for Enhanced API Reporting and Legitimate Accountability for Base Entity Listings Act'' or the ``CLEAR LABELS Act''. SEC. 2. REQUIRE DRUG LABELING TO INCLUDE ORIGINAL MANUFACTURER AND SUPPLY CHAIN INFORMATION. Section 502(b) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 352(b)) is amended to read as follows: ``(b)(1) If it is a finished drug product in a package form, unless it bears a label containing-- ``(A) the name, place of business, and unique facility identifier of the manufacturer, packer, or distributor or a link, barcode, QR code, or other means to access a searchable electronic portal containing such information; and ``(B) an accurate statement of the quantity of the contents in terms of weight, measure, or numerical count, provided that under this clause reasonable variations shall be permitted, and exemptions as to small packages shall be established, by regulations prescribed by the Secretary. ``(2) If it is an active pharmaceutical ingredient, unless any accompanying label and certificate of analysis contains the name, place of business, and unique facility identifier of the original manufacturer. ``(3)(A) If it is a finished drug product, unless its labeling contains the name, place of business, and unique facility identifier of-- ``(i) the original manufacturer of each active pharmaceutical ingredient; ``(ii) the original manufacturer of the finished drug product; and ``(iii) the packer or distributor, if any, or a link, barcode, QR code, or other means to access a searchable electronic portal containing such information. ``(B) In the case of a finished drug product for which there are multiple potential different manufacturers of the active pharmaceutical ingredient, the requirements of this subparagraph shall be satisfied if all such manufacturers of active pharmaceutical ingredients for the drug product are identified in the labeling or the searchable electronic portal. ``(4) A manufacturer, packer, or distributor required to furnish information under subparagraphs (1), (2), and (3), in addition to making such information available electronically, as applicable, shall make such information available through a package insert, or in paper copy to any individual who requests such a copy. ``(5) For purposes of this paragraph, the term `original manufacturer', means the single last establishment to conduct substantial manufacturing activities prior to introduction of the active pharmaceutical ingredient or finished drug product into interstate commerce. ``(6) The Secretary shall issue regulations to implement subparagraphs (2) and (3) and may provide for reasonable variations in the implementation of, or an alternative placement for, the labeling requirements under such subparagraphs, including by electronic means. Such regulations shall take effect on a date determined by the Secretary and not earlier than 1 year after the date of publication of the final regulations, and shall apply with respect to drugs manufactured on or after the effective date of such regulations.''. SEC. 3. EXEMPTION FROM CUSTOMS COUNTRY OF ORIGIN MARKING REQUIREMENT. Section 304 of the Tariff Act of 1930 (19 U.S.C. 1304) is amended by adding at the end the following: ``(m) Marking of Certain Finished Drug Products.--The marking requirements of subsections (a) and (b) shall not apply to articles that are finished drug products and are marked in accordance with the requirements of section 502(b)(3)(A) of the Federal Food, Drug, and Cosmetic Act.''. <all>\n\nSUMMARY TO EVALUATE:\nTitle: CLEAR LABELS Act: New transparency rules for drug manufacturing and ingredients\nSummary: This act requires drug labels to clearly identify the original manufacturers of both the finished medicine and its active ingredients. Patients will be able to access detailed supply chain information through QR codes, websites, or paper copies.\nKey Points: Mandatory labeling of the original manufacturer for all finished drug products., Requirement to disclose the source of active pharmaceutical ingredients (APIs)., Access to manufacturer data via searchable electronic portals or QR codes., Right to request a paper copy of the manufacturing and supply chain information., New standards for identifying the 'original manufacturer' to ensure accountability.\n\nZASADY OCENY:\n1. Sprawdź wszystkie LICZBY, DATY i KWOTY w SUMMARY. Jeśli którejś brakuje w SOURCE -> is_valid: false.\n2. Sprawdź wszystkie NAZWISKA, ORGANIZACJE i MIEJSCA w SUMMARY. Jeśli którejś brakuje w SOURCE -> is_valid: false.\n3. Sprawdź wszystkie konkretne DZIAŁANIA PRAWNE . Jeśli tego mechanizmu nie ma w SOURCE -> is_valid: false.\n\nWAŻNE: Abstrakcyjne pojęcia (np. \"transparentność\", \"zaufanie\") są dozwolone jako wnioski.\n\nOUTPUT (JSON):\n{\n  \"is_valid\": true/false,\n  \"issue\": \"fabricated_entity\" / \"contradiction\" / \"none\"\n}\n\nWYMAGANIA FORMATOWANIA:\n1. Odpowiedz WYŁĄCZNIE surowym obiektem JSON.\n2. NIE używaj bloków kodu Markdown.\n3. NIE dodawaj żadnych wstępów ani wyjaśnień przed ani po JSONie.\n4. JSON musi być poprawny i gotowy do parsowania.\n\n",
      "ai_response_raw": "{\n  \"is_valid\": true,\n  \"issue\": \"none\"\n}"
    },
    {
      "timestamp": "2026-04-18T11:15:21.293Z",
      "source_url": "https://www.congress.gov/119/bills/hr8269/BILLS-119hr8269ih.htm",
      "model": "gemini-flash-latest",
      "prompt_sent": "\nJesteś ekspertem od prawa Stanów Zjednoczonych, który ma za zadanie analizować dokumenty ustaw, uchwał oraz innych dokumentów legislacyjnych, a następnie przygotowywać z nich informacje w przystępny sposób dla obywateli. Twoim celem jest przedstawienie informacji tak, aby obywatele mogli sami ocenić wpływ legislacji na ich życie, nawet bez posiadania specjalistycznej wiedzy legislacyjnej. Skup się na faktach i obiektywnych skutkach wprowadzanych zmian, unikając wartościowania i osobistych opinii. Wszelki żargon prawny jest zabroniony. Prezentuj informacje w jasny, zwięzły i angażujący sposób, tak aby były zrozumiałe dla osoby bez wykształcenia prawniczego. Unikaj długich, złożonych zdań. Zamiast pisać \"projekt ma na celu nowelizację kodeksu podatkowego...\", napisz \"Zmiany w podatkach: nowe ulgi i obowiązki dla...\". Kontynuuj swoją pracę, dopóki nie rozwiążesz swojego zadania. Jeśli nie masz pewności co do generowanej treści, przeanalizuj dokument ponownie – nie zgaduj. Rozplanuj dobrze swoje zadanie przed przystąpieniem do niego. W podsumowaniu i kluczowych punktach, jeśli to możliwe i uzasadnione, podkreśl, jakie konkretne korzyści lub skutki (pozytywne lub negatywne) wprowadza ustawa dla życia codziennego obywateli, ich praw i obowiązków, finansów osobistych, bezpieczeństwa i innych ważnych kwestii (np. kategorycznych zakazów i nakazów czy najważniejszych konkretnych alokacji finansowych i terytorialnych).\n\nTwoja odpowiedź MUSI być w formacie JSON - i zawierać następujące klucze.\nZanim zwrócisz odpowiedź, dokładnie zweryfikuj, czy cała struktura JSON jest w 100% poprawna, włącznie ze wszystkimi przecinkami, nawiasami klamrowymi, kwadratowymi oraz cudzysłowami. Błędny JSON jest nieakceptowalny i uniemożliwi przetworzenie Twojej pracy.\n\nPrzeanalizuj dokładnie poniższy tekst dokumentu prawnego. To jest treść, na podstawie której masz wygenerować podsumowanie i kluczowe punkty:\n--- POCZĄTEK DOKUMENTU ---\n[Congressional Bills 119th Congress] [From the U.S. Government Publishing Office] [H.R. 8269 Introduced in House (IH)] <DOC> 119th CONGRESS 2d Session H. R. 8269 To amend the Federal Food, Drug, and Cosmetic Act to require drug labeling to include original manufacturer and supply chain information. _______________________________________________________________________ IN THE HOUSE OF REPRESENTATIVES April 14, 2026 Mr. McCormick (for himself and Ms. DeLauro) introduced the following bill; which was referred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned _______________________________________________________________________ A BILL To amend the Federal Food, Drug, and Cosmetic Act to require drug labeling to include original manufacturer and supply chain information. Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled, SECTION 1. SHORT TITLE. This Act may be cited as the ``Consumer Labeling for Enhanced API Reporting and Legitimate Accountability for Base Entity Listings Act'' or the ``CLEAR LABELS Act''. SEC. 2. REQUIRE DRUG LABELING TO INCLUDE ORIGINAL MANUFACTURER AND SUPPLY CHAIN INFORMATION. Section 502(b) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 352(b)) is amended to read as follows: ``(b)(1) If it is a finished drug product in a package form, unless it bears a label containing-- ``(A) the name, place of business, and unique facility identifier of the manufacturer, packer, or distributor or a link, barcode, QR code, or other means to access a searchable electronic portal containing such information; and ``(B) an accurate statement of the quantity of the contents in terms of weight, measure, or numerical count, provided that under this clause reasonable variations shall be permitted, and exemptions as to small packages shall be established, by regulations prescribed by the Secretary. ``(2) If it is an active pharmaceutical ingredient, unless any accompanying label and certificate of analysis contains the name, place of business, and unique facility identifier of the original manufacturer. ``(3)(A) If it is a finished drug product, unless its labeling contains the name, place of business, and unique facility identifier of-- ``(i) the original manufacturer of each active pharmaceutical ingredient; ``(ii) the original manufacturer of the finished drug product; and ``(iii) the packer or distributor, if any, or a link, barcode, QR code, or other means to access a searchable electronic portal containing such information. ``(B) In the case of a finished drug product for which there are multiple potential different manufacturers of the active pharmaceutical ingredient, the requirements of this subparagraph shall be satisfied if all such manufacturers of active pharmaceutical ingredients for the drug product are identified in the labeling or the searchable electronic portal. ``(4) A manufacturer, packer, or distributor required to furnish information under subparagraphs (1), (2), and (3), in addition to making such information available electronically, as applicable, shall make such information available through a package insert, or in paper copy to any individual who requests such a copy. ``(5) For purposes of this paragraph, the term `original manufacturer', means the single last establishment to conduct substantial manufacturing activities prior to introduction of the active pharmaceutical ingredient or finished drug product into interstate commerce. ``(6) The Secretary shall issue regulations to implement subparagraphs (2) and (3) and may provide for reasonable variations in the implementation of, or an alternative placement for, the labeling requirements under such subparagraphs, including by electronic means. Such regulations shall take effect on a date determined by the Secretary and not earlier than 1 year after the date of publication of the final regulations, and shall apply with respect to drugs manufactured on or after the effective date of such regulations.''. SEC. 3. EXEMPTION FROM CUSTOMS COUNTRY OF ORIGIN MARKING REQUIREMENT. Section 304 of the Tariff Act of 1930 (19 U.S.C. 1304) is amended by adding at the end the following: ``(m) Marking of Certain Finished Drug Products.--The marking requirements of subsections (a) and (b) shall not apply to articles that are finished drug products and are marked in accordance with the requirements of section 502(b)(3)(A) of the Federal Food, Drug, and Cosmetic Act.''. <all>\n--- KONIEC DOKUMENTU ---\n\nPAMIĘTAJ: Twoja odpowiedź MUSI być wyłącznie poprawnym obiektem JSON. Nie dodawaj żadnych dodatkowych znaków, komentarzy ani tekstu przed znacznikiem '{' ani po znaczniku '}'. Cała odpowiedź musi być parsowalna jako JSON.\nNa podstawie POWYŻSZEGO dokumentu, wypełnij poniższą strukturę JSON:\nOto struktura JSON, której oczekuję (wypełnij ją treścią):\n{\n  \"pl_ai_title\": \"Nowy, krótki tytuł dla aktu prawnego po polsku, oddający sedno wprowadzanych zmian (np. maksymalnie 10-12 słów).\",\n  \"pl_summary\": \"2-3 zdania zwięzłego podsumowania treści aktu prawnego po polsku, napisane z perspektywy wpływu na życie codzienne obywateli.\",\n  \"pl_key_points\": [\n    \"Pierwszy krótki punkt po polsku dotyczący najważniejszych wprowadzanych rozwiązań lub zmian.\",\n    \"Drugi krótki punkt po polsku...\"\n  ],\n  \"eng_ai_title\": \"A new, short title for the legal act in English, capturing the essence of the changes (e.g., max 10-12 words).\",\n  \"eng_summary\": \"2-3 sentences summarizing the legal act in English, from the perspective of its impact on citizens' daily lives.\",\n  \"eng_key_points\": [\n    \"First short bullet point in English regarding the most important solutions or changes being introduced.\",\n    \"Second short bullet point in English...\"\n  ],\n  \"de_ai_title\": \"Ein neuer, kurzer Titel für das Rechtsdokument auf Deutsch, der den Kern der Änderungen erfasst (z.B. max. 10-12 Wörter).\",\n  \"de_summary\": \"2-3 Sätze Zusammenfassung des Rechtsdokuments auf Deutsch, aus der Perspektive seiner Auswirkungen auf das tägliche Leben der Bürger.\",\n  \"de_key_points\": [\n    \"Erster kurzer Stichpunkt auf Deutsch zu den wichtigsten eingeführten Lösungen oder Änderungen.\",\n    \"Zweiter kurzer Stichpunkt auf Deutsch...\"\n  ],\n  \"fr_ai_title\": \"Un nouveau titre court pour l'acte juridique en français, saisissant l'essence des changements (par exemple, 10-12 mots maximum).\",\n  \"fr_summary\": \"Résumé de 2-3 phrases de l'acte juridique en français, du point de vue de son impact sur la vie quotidienne des citoyens.\",\n  \"fr_key_points\": [\n    \"Premier court point en français concernant les solutions ou changements les plus importants introduits.\",\n    \"Deuxième court point en français...\"\n  ],\n  \"es_ai_title\": \"Un nuevo título breve para el acto jurídico en español, que recoja la esencia de los cambios (por ejemplo, máximo 10-12 palabras).\",\n  \"es_summary\": \"Resumen de 2-3 frases del acto jurídico en español, desde la perspectiva de su impacto en la vida cotidiana de los ciudadanos.\",\n  \"es_key_points\": [\n    \"Primer punto breve en español sobre las soluciones o cambios más importantes que se introducen.\",\n    \"Segundo punto breve en español...\"\n  ],\n  \"it_ai_title\": \"Un nuovo titolo breve per l'atto giuridico in italiano, che colga l'essenza delle modifiche (ad es. massimo 10-12 parole).\",\n  \"it_summary\": \"Riepilogo di 2-3 frasi dell'atto giuridico in italiano, dal punto di vista del suo impatto sulla vita quotidiana dei cittadini.\",\n  \"it_key_points\": [\n    \"Primo breve punto in italiano riguardante le soluzioni o le modifiche più importanti introdotte.\",\n    \"Secondo breve punto in italiano...\"\n  ],\n  \"nl_ai_title\": \"Een nieuwe, korte titel voor de rechtshandeling in het Nederlands, die de essentie van de wijzigingen weergeeft (bijv. max. 10-12 woorden).\",\n  \"nl_summary\": \"Samenvatting van 2-3 zinnen van de rechtshandeling in het Nederlands, vanuit het perspectief van de impact op het dagelijks leven van burgers.\",\n  \"nl_key_points\": [\n    \"Eerste korte punt in het Nederlands betreffende de belangrijkste geïntroduceerde oplossingen of wijzigingen.\",\n    \"Tweede korte punt in het Nederlands...\"\n  ],\n  \"pt_ai_title\": \"Um novo título curto para o ato jurídico em português, capturando a essência das mudanças (por exemplo, máx. 10-12 palavras).\",\n  \"pt_summary\": \"Resumo de 2-3 frases do ato jurídico em português, na perspetiva do seu impacto na vida quotidiana dos cidadãos.\",\n  \"pt_key_points\": [\n    \"Primeiro ponto curto em português sobre as soluções ou alterações mais importantes introduzidas.\",\n    \"Segundo ponto curto em português...\"\n  ],\n  \"category\": [\"Categorize the document into one category by default, based on the field it primarily concerns. Choose up to 3 if the document also touches upon SIGNIFICANT issues from other categories. You MUST select categories ONLY from the following list: Health, Education, Family, Taxes, Labor, Security, Environment, Courts and Law, Transport, Benefits, Real Estate, Media and Culture, Local Government, Migration, Agriculture, Public Investments, Informatization, Economy. If the document does not definitively fit any of these, you MUST use \"Other\". If you use \"Other\", it should be the ONLY category selected. Do NOT invent new categories. The response must be an array of strings, e.g., [\"Taxes\", \"Family\"].\"]\n}\n\n",
      "ai_response_raw": "{\n  \"pl_ai_title\": \"Ustawa CLEAR LABELS: Większa przejrzystość pochodzenia leków i ich składników\",\n  \"pl_summary\": \"Nowe przepisy nakładają na producentów obowiązek informowania o tym, kto dokładnie wyprodukował lek oraz jego główne składniki aktywne. Dzięki temu pacjenci zyskają łatwiejszy dostęp do danych o pochodzeniu swoich lekarstw poprzez kody QR, strony internetowe lub ulotki.\",\n  \"pl_key_points\": [\n    \"Obowiązek podawania nazwy i lokalizacji faktycznego producenta leku na opakowaniu.\",\n    \"Wymóg ujawniania producenta głównego składnika aktywnego (API) znajdującego się w leku.\",\n    \"Możliwość sprawdzenia szczegółów łańcucha dostaw za pomocą kodów QR lub specjalnych portali internetowych.\",\n    \"Gwarancja otrzymania informacji o producentach w formie papierowej na żądanie pacjenta.\",\n    \"Wprowadzenie jasnej definicji 'oryginalnego producenta' jako podmiotu faktycznie wytwarzającego produkt.\"\n  ],\n  \"eng_ai_title\": \"CLEAR LABELS Act: New transparency rules for drug manufacturing and ingredients\",\n  \"eng_summary\": \"This act requires drug labels to clearly identify the original manufacturers of both the finished medicine and its active ingredients. Patients will be able to access detailed supply chain information through QR codes, websites, or paper copies.\",\n  \"eng_key_points\": [\n    \"Mandatory labeling of the original manufacturer for all finished drug products.\",\n    \"Requirement to disclose the source of active pharmaceutical ingredients (APIs).\",\n    \"Access to manufacturer data via searchable electronic portals or QR codes.\",\n    \"Right to request a paper copy of the manufacturing and supply chain information.\",\n    \"New standards for identifying the 'original manufacturer' to ensure accountability.\"\n  ],\n  \"de_ai_title\": \"CLEAR LABELS Gesetz: Mehr Transparenz bei der Herkunft von Medikamenten\",\n  \"de_summary\": \"Dieses Gesetz verpflichtet Hersteller dazu, den tatsächlichen Ursprung von Medikamenten und deren Wirkstoffen offenzulegen. Bürger können Informationen über die Herstellungsorte künftig einfach per QR-Code oder auf Anfrage in Papierform abrufen.\",\n  \"de_key_points\": [\n    \"Pflicht zur Angabe des ursprünglichen Herstellers auf der Medikamentenverpackung.\",\n    \"Offenlegung der Herkunft der aktiven pharmazeutischen Wirkstoffe (API).\",\n    \"Einführung von QR-Codes und Online-Portalen für den schnellen Zugriff auf Lieferkettendaten.\",\n    \"Anspruch auf eine Papierkopie der Herstellerinformationen für jeden Verbraucher.\",\n    \"Vereinfachung der Kennzeichnungsvorschriften für importierte Arzneimittel.\"\n  ],\n  \"fr_ai_title\": \"Loi CLEAR LABELS : Transparence accrue sur l'origine des médicaments et ingrédients\",\n  \"fr_summary\": \"Cette loi impose aux fabricants d'indiquer précisément qui a produit le médicament et ses composants actifs. Les citoyens pourront vérifier l'origine de leurs traitements via des codes QR ou des documents papier sur demande.\",\n  \"fr_key_points\": [\n    \"Obligation d'indiquer le nom et le lieu du fabricant d'origine sur l'étiquette.\",\n    \"Transparence sur la provenance des principes actifs (API) utilisés dans le médicament.\",\n    \"Accès aux informations via des portails électroniques, des liens ou des codes QR.\",\n    \"Possibilité d'obtenir ces informations sur support papier sur simple demande.\",\n    \"Nouvelles règles pour l'identification de l'établissement responsable de la fabrication.\"\n  ],\n  \"es_ai_title\": \"Ley CLEAR LABELS: Mayor transparencia en el origen de medicamentos e ingredientes\",\n  \"es_summary\": \"Esta ley exige que las etiquetas de los medicamentos identifiquen claramente a los fabricantes originales del producto y de sus ingredientes activos. Los ciudadanos podrán acceder a esta información mediante códigos QR o solicitando copias en papel.\",\n  \"es_key_points\": [\n    \"Obligación de incluir el nombre y ubicación del fabricante original en el envase.\",\n    \"Requisito de informar sobre el origen de los ingredientes farmacéuticos activos (API).\",\n    \"Acceso a datos de la cadena de suministro a través de portales electrónicos o códigos QR.\",\n    \"Derecho a recibir la información del fabricante en formato papel si se solicita.\",\n    \"Simplificación de las reglas de marcado de país de origen para productos farmacéuticos.\"\n  ],\n  \"it_ai_title\": \"Legge CLEAR LABELS: Trasparenza sull'origine dei farmaci e dei loro ingredienti\",\n  \"it_summary\": \"Questa legge impone ai produttori di indicare chiaramente chi ha realizzato il farmaco e i suoi principi attivi. I cittadini avranno accesso ai dettagli sulla provenienza dei medicinali tramite codici QR o moduli cartacei.\",\n  \"it_key_points\": [\n    \"Obbligo di riportare il nome e la sede del produttore originale sull'etichetta.\",\n    \"Trasparenza sulla provenienza dei principi attivi farmaceutici (API).\",\n    \"Accesso alle informazioni sulla catena di fornitura tramite portali web o codici QR.\",\n    \"Diritto di richiedere una copia cartacea delle informazioni sulla produzione.\",\n    \"Nuove norme per identificare l'ultimo stabilimento responsabile della fabbricazione.\"\n  ],\n  \"nl_ai_title\": \"CLEAR LABELS Act: Meer transparantie over de herkomst van medicijnen\",\n  \"nl_summary\": \"Deze wet verplicht fabrikanten om de oorspronkelijke producent van medicijnen en hun werkzame stoffen te vermelden. Burgers kunnen de herkomst van hun medicatie eenvoudig controleren via QR-codes of papieren bijsluiters.\",\n  \"nl_key_points\": [\n    \"Verplichte vermelding van de oorspronkelijke fabrikant op de verpakking van medicijnen.\",\n    \"Openbaarmaking van de herkomst van actieve farmaceutische bestanddelen (API's).\",\n    \"Toegang tot informatie over de toeleveringsketen via QR-codes of online portalen.\",\n    \"Recht op een papieren kopie van de fabrikantinformatie op verzoek.\",\n    \"Nieuwe regels voor de definitie van de 'oorspronkelijke fabrikant' voor betere verantwoording.\"\n  ],\n  \"pt_ai_title\": \"Lei CLEAR LABELS: Transparência na origem de medicamentos e ingredientes ativos\",\n  \"pt_summary\": \"Esta lei exige que os rótulos dos medicamentos identifiquem os fabricantes originais do produto final e dos seus ingredientes ativos. Os cidadãos poderão consultar a origem dos seus remédios através de códigos QR ou pedidos em papel.\",\n  \"pt_key_points\": [\n    \"Obrigatoriedade de listar o nome e local do fabricante original na embalagem.\",\n    \"Exigência de informar a origem dos ingredientes farmacêuticos ativos (API).\",\n    \"Acesso a informações da cadeia de suprimentos via portais eletrónicos ou códigos QR.\",\n    \"Garantia de acesso a informações em papel para quem as solicitar.\",\n    \"Isenção de certas marcações alfandegárias se as novas regras de rotulagem forem seguidas.\"\n  ],\n  \"category\": [\n    \"Health\",\n    \"Economy\"\n  ]\n}"
    }
  ]
}